Hyponatremia remains the most common electrolyte disorder in clinical practice, with a wide range of causes ranging from endocrine dysregulation to iatrogenic causes. Recent developments in point-of-care ultrasonography, vasopressin physiology, and osmoregulation have transformed diagnostics by emphasizing accuracy above purely clinical judgment. Although traditional management based on fluid restriction and hypertonic solutions remain the cornerstone of treatment, a careful and cautious monitoring is required to avoid osmotic demyelination and overcorrection. The Furst equation, a validated predictor of response to fluid restriction, should be integrated into routine practice, together with objective tools such as point-of-care ultrasonography, to improve the accuracy of volume assessment and guide more precise therapeutic decisions. Likewise, different therapeutic options have been studied for non-responders to fluid restriction, including urea, desmopressin, and selective vasopressin receptor antagonists (vaptans), showing promising results. Ongoing developments in artificial intelligence and laboratory-based decision support tools are expected to improve personalized management and predictive accuracy, potentially reconciling the disparity between evidence and clinical practice.
Alopecia areata (AA) is a common autoimmune disease characterized by nonscarring hair loss, yet real-world data on AA in Mexico are sparse. This study aimed to characterize disease burden and identify unmet treatment needs among patients with AA in Mexico. Clinical data were analyzed from Adelphi Real World’s AA II Mexico Disease Specific Programme™ (October 2024–April 2025), a linked physician and patient cross-sectional survey with retrospective elements. Dermatologists provided clinical and treatment information for eight consecutive patients with AA within prespecified severity quotas (three mild, three moderate, and two severe/very severe). Patients completed the Hospital Anxiety and Depression Scale, the Alopecia Areata Patient Priority Outcomes instrument, and the Skindex-16 AA questionnaire. Analyses were stratified by physician-assessed AA severity (mild, moderate, severe/very severe). Of the 319 patients included, 123 had mild, 112 moderate, and 84 severe/very severe AA. Disease duration, percent scalp hair loss, nonscalp hair loss (eyebrow, eyelash, and body), and hair regrowth at consultation differed significantly across severity groups. Traditional medications, such as intralesional, topical, and oral corticosteroids, were the most frequently prescribed treatments across all severity groups. Physician-reported satisfaction with current treatment decreased with increasing AA severity and was significantly different across severity groups (P < 0.0001). Overall, 23.0
INTRODUCTION:Nosocomial infections (NIs) in cirrhosis are associated with high mortality but could be preventable. Logistic regression (LR) models have failed to identify high-risk patients. We aimed to develop machine learning (ML) models to predict NI. METHODS:The CLEARED consortium consists of prospectively enrolled cirrhosis inpatients from >120 centers. Using day-of-admission clinical data, 3 ML approaches (random forest [RF], extreme gradient boosting, and neural networks [NNs]) were used to predict NI. Data were split 80:20 for training and testing stratified by the outcome. Models were compared using area under the receiver operating characteristic curve (AUC). RESULTS:In total, 8,263 patients (55.90 ± 13.34 years; 64.1% men) from 127 centers in 37 countries were included. NI developed in 869 (10.5%), a median of 6 (4-11) days of postadmission. Major NIs were respiratory (29.6%) and urinary tract infection (15.7%), and spontaneous bacterial peritonitis (13.5%). NIs occurred more frequently in patients from low/low-middle income countries and those with severe liver disease, alcohol etiology, and admission infections. NIs were associated with inpatient mortality (31.9% vs 8.1%, P < 0.001) and liver transplantation (4.8% vs 1.9%, P < 0.001). Although the RF model (AUC 0.69) showed good calibration (Brier score 0.09), outperforming extreme gradient boosting, neural network, and LR models (AUC 0.66 for all; LR comparison P = 0.043), no model achieved AUC ≥0.80 for clinical utility. At 10% predicted probability threshold, the RF model demonstrated only 75.4% sensitivity, 52.9% specificity, and 15.9% positive predictive value (PPV). DISCUSSION:NIs cannot be accurately predicted from day-of-admission data using ML models, even in a large, prospective, global cirrhosis cohort. Every hospitalized patient with cirrhosis should receive protocolized infection control measures.
Introduction and Objectives Delayed diagnostic paracentesis has been associated with worse outcomes in patients with decompensated cirrhosis and suspected spontaneous bacterial peritonitis (SBP). Data from Latin American populations remain limited.To evaluate the association between early paracentesis (24 hours from hospital admission) and in-hospital mortality in patients with decompensated cirrhosis and suspected SBP. Materials and Methods Retrospective observational study including hospitalized adults with decompensated cirrhosis and SBP. Patients were classified according to the timing of paracentesis: early (24 hours) or delayed (>24 hours). Clinical, laboratory, and survival outcomes were compared between groups. Cox regression analysis was performed to evaluate the association between early paracentesis and in-hospital mortality. Results A total of 102 patients were included. Mean age was 54.7±13.6 years, and 63.7% were men. Early paracentesis was performed in 33.3% of patients, whereas 66.7% underwent delayed paracentesis. In-hospital mortality was significantly lower in the early paracentesis group compared with the delayed group (38.2% vs 61.8%, p=0.021). Six-month survival was also higher in patients undergoing early paracentesis (58.8% vs 38.8%, p=0.045). Patients with delayed paracentesis had significantly higher bilirubin levels (14.02 vs 4.52 mg/dL, p=0.007), AST (104.5 vs 59.5 U/L, p=0.001), and ALT levels (52.5 vs 31.5 U/L, p=0.004). On Cox regression analysis, early paracentesis was independently associated with lower in-hospital mortality (HR 0.383, 95% CI 0.164–0.894, p=0.026). Conclusions Early paracentesis within the first 24 hours of admission was independently associated with lower in-hospital mortality in patients with decompensated cirrhosis and suspected SBP. Timely diagnostic paracentesis may represent an important quality-of-care measure.
Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease and predominantly affects older adults. In recent years, dipeptidyl peptidase-4 inhibitors (DPP-4i), widely prescribed for type 2 diabetes mellitus, have emerged as important pharmacologic triggers of BP. DPP-4 inhibitors as a class have been associated with BP, with the strongest evidence reported for vildagliptin, although cases involving linagliptin have also been documented. Linagliptin has also been increasingly recognized as a potential trigger of drug-associated disease. We report the case of an 81-year-old woman with long-standing type 2 diabetes mellitus treated with metformin and linagliptin who developed a generalized pruritic vesiculobullous eruption. Dermatologic examination demonstrated multiple tense bullae, erosions, crusted plaques, and post-inflammatory hyperpigmented lesions involving the trunk, extremities, and intertriginous regions. Histopathologic examination revealed a subepidermal blister with prominent eosinophilic infiltration. Direct immunofluorescence demonstrated linear C3 and IgG deposition along the basement membrane zone, while indirect immunofluorescence localized immunoreactants to the roof of the split, confirming the diagnosis of BP. The temporal association with linagliptin exposure and the absence of alternative triggers supported the diagnosis of DPP-4 inhibitor-associated BP. Linagliptin was discontinued, and treatment with prednisone was initiated, resulting in progressive improvement and complete cessation of new blister formation at follow-up. This case highlights the importance of recognizing medication-induced BP in older diabetic patients and reviews current evidence regarding the epidemiology, pathogenesis, clinical presentation, diagnosis, and management of DPP-4 inhibitor-associated BP.